Luveniq Advisory Committee: Renal Side Effects May Be Key Issue With Immunosuppressant

Lux Biosciences' Luveniq (voclosporin) for uveitis will undergo review by FDA's Dermatologic and Ophthalmic Drugs Advisory Committee on June 28.